EUMYTIC EUMYTIC FLEXAGIL FLEXAGIL EMRIX EMRIX EMRIX EMRIX ZAPRALDA MEZREL XR MEZREL XR MEZREL XR MEZREL XR NEXTFLEX NEXTFLEX DYSOPRIN COMFORTA

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

It belongs to Muscle Relaxants pharmacological group on the basis of mechanism of action. The Molecular Weight of cyclobenzaprine hydrochloride is 311.90. Its pKa is 8.47.

cyclobenzaprine hydrochloride is contraindicated in conditions like Hyperthyroidism,Congestive heart failure,Hypersensitivity to any component of product.

The severe or irreversible adverse effects of cyclobenzaprine hydrochloride, which give rise to further complications include Irregular heart beat.cyclobenzaprine hydrochloride produces potentially life-threatening effects which include Hypersensitivity reactions. which are responsible for the discontinuation of cyclobenzaprine hydrochloride therapy.The signs and symptoms that are produced after the acute overdosage of cyclobenzaprine hydrochloride include Nausea, Vomiting, Tachycardia, Coma, Seizures, Cardiac dysrhythmias, Drowsiness, Changes in ECG, Confusion, Hallucinations, Ataxia, Severe hypotension, Dizziness, Tremor, Agitation, Hypertension, Slurred speech.The symptomatic adverse reactions produced by cyclobenzaprine hydrochloride are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Drowsiness, Fatigue, Nausea, Diarrhea, Constipation, Abdominal pain, Dry mouth, Acid regurgitation.

cyclobenzaprine hydrochloride is primarily indicated in conditions like Muscle relaxation, Muscular spasm, Pain.

cyclobenzaprine hydrochloride is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAlprazolamCentral nervous system- and/or respiratory-depressant effects may be additively or synergistically increased.MajorDuring concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.Indacaterolconcomitant therapy prolong QTc interval monitor closelyIpriflavoneQuetiapineAgents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.MajorCaution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.Selegiline (HCl)Coadministration of monoamine oxidase inhibitors (MAOIs) and dibenzazepine derivatives (e.g., tricyclic and tetracyclic antidepressants, cyclobenzaprine, carbamazepine) may rarely produce significant adverse reactions including nausea, vomiting, flushing, dizziness, tremor, myoclonus, rigidity, diaphoresis, hyperthermia, autonomic instability, hypertensive crises, disseminated intravascular coagulation, severe convulsive seizures, coma, and death. The exact mechanism is unknown but may be related to excessive serotonergic activity in the CNS (i.e. serotonin syndrome).MajorIn general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity. At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with tricyclic antidepressants, and vice versaTramadol (HCl)The risk of seizures may be increased during coadministration with tramadol. MajorCaution is advised if tramadol is administered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with epilepsya history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections). These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to patients suffering from Liver Malfunction.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

tablet Store Between 15°C-30°C.

Use of Cyclobenzaprine Hydrochloride for periods longer than two or three weeks is not recommended. Less frequent dosing should be considered for hepatically impaired or elderly patients. It is contraindicated in acute recovery phase of myocardial infarction, and patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure. it should be used with caution in elderly patients with reduced doses. It should be used with caution in patients with a history of urinary retention, angleclosure glaucoma, increased intraocular pressure, and in patients taking anticholinergic medication. It should be used with caution in subjects with mild hepatic impairment starting with a 5 mg dose and titrating slowly upward. In subjects with moderate to severe impairment is not recommended. Safety and effectiveness of cyclobenzaprine hydrochloride in pediatric patients below 15 years of age have not been established.